Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials

The Lancet Respiratory Medicine

Volumn 6, Issue 7, 2018, Pages 511-525

  Panettieri, Reynold A ^a,b   Sjöbring, Ulf ^c   Péterffy, AnnaMaria ^c   Wessman, Peter ^c   Bowen, Karin ^d   Piper, Edward ^d   Colice, Gene ^d   Brightling, Christopher E ^e  

^a The State University of New Jersey   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c ASTRAZENECA R AND D   (Sweden)

^d ASTRAZENECA   (United Kingdom)

^e UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; PLACEBO; TRALOKINUMAB; MONOCLONAL ANTIBODY;

ADULT; AGED; ALLERGIC PNEUMONITIS; ARTICLE; ASTHMA; AUTOIMMUNE DISEASE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; COLON CANCER; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; EOSINOPHILIC GRANULOMA; FEMALE; FRACTIONAL EXHALED NITRIC OXIDE; HEART ARREST; HEART INFARCTION; HUMAN; INJECTION SITE REACTION; INTESTINE OBSTRUCTION; INTESTINE PERFORATION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; OUTCOME ASSESSMENT; PERITONITIS; PHASE 3 CLINICAL TRIAL; POLYANGIITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RISK BENEFIT ANALYSIS; SEPTIC SHOCK; TOTAL QUALITY MANAGEMENT; TREATMENT DURATION; UROSEPSIS; ADOLESCENT; CHILD; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ASTHMA; CHILD; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85047094341     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(18)30184-X     Document Type: Article

References (45)

1. To, T, Stanojevic, S, Moores, G, et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health, 12, 2012, 204.
2. Chung, KF, Wenzel, SE, Brozek, JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 43 (2014), 343–373.
3. Global Initiative for Asthma. Global strategy for asthma management and prevention. http://ginasthma.org/2017-gina-report-global-strategy-for-asthma-management-and-prevention/, 2017. (Accessed 15 August 2017)
4. Sadatsafavi, M, Lynd, L, Marra, C, et al. Direct health care costs associated with asthma in British Columbia. Can Respir J 17 (2010), 74–80.
5. Hankin, S, Bronstone, A, Wang, Z, Buatti Small, M, Buck, P, Estimated prevalence and economic burden of severe, uncontrolled asthma in the United States. J Allergy Clin Immunol, 131(suppl 2), 2013 AB126 (abstr 454).
6. Wills-Karp, M, Luyimbazi, J, Xu, X, et al. Interleukin-13: central mediator of allergic asthma. Science 282 (1998), 2258–2261.
7. Grunig, G, Warnock, M, Wakil, AE, et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 282 (1998), 2261–2263.
8. Batra, V, Musani, AI, Hastie, AT, et al. Bronchoalveolar lavage fluid concentrations of transforming growth factor (TGF)-β1, TGF-β2, interleukin (IL)-4 and IL-13 after segmental allergen challenge and their effects on alpha-smooth muscle actin and collagen III synthesis by primary human lung fibroblasts. Clin Exp Allergy 34 (2004), 437–444.
9. Firszt, R, Francisco, D, Church, TD, Thomas, JM, Ingram, JL, Kraft, M, Interleukin-13 induces collagen type-1 expression through matrix metalloproteinase-2 and transforming growth factor-β1 in airway fibroblasts in asthma. Eur Respir J 43 (2014), 464–473.
10. Chiba, Y, Nakazawa, S, Todoroki, M, Shinozaki, K, Sakai, H, Misawa, M, Interleukin-13 augments bronchial smooth muscle contractility with an up-regulation of RhoA protein. Am J Respir Cell Mol Biol 40 (2009), 159–167.
11. Humbert, M, Durham, SR, Kimmitt, P, et al. Elevated expression of messenger ribonucleic acid encoding IL-13 in the bronchial mucosa of atopic and nonatopic subjects with asthma. J Allergy Clin Immunol 99 (1997), 657–665.
12. Kotsimbos, TC, Ernst, P, Hamid, QA, Interleukin-13 and interleukin-4 are coexpressed in atopic asthma. Proc Assoc Am Physicians 108 (1996), 368–373.
13. Saha, SK, Berry, MA, Parker, D, et al. Increased sputum and bronchial biopsy IL-13 expression in severe asthma. J Allergy Clin Immunol 121 (2008), 685–691.
14. Popovic, B, Breed, J, Rees, DG, et al. Structural characterisation reveals mechanism of IL-13 neutralising monoclonal antibody tralokinumab as inhibition of binding to IL-13Rα1 and IL-13Rα2. J Mol Biol 429 (2017), 208–219.
15. Piper, E, Brightling, C, Niven, R, et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J 41 (2013), 330–338.
16. Brightling, CE, Chanez, P, Leigh, R, et al. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med 3 (2015), 692–701.
17. Wenzel, SE, Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 18 (2012), 716–725.
18. Panettieri, R, Wang, M, Braddock, M, Bowen, K, Colice, G, Tralokinumab for the treatment of severe, uncontrolled asthma: the ATMOSPHERE clinical development program. Immunotherapy 10 (2018), 473–490.
19. Panettieri, RA Jr., Brightling, C, Sjobring, U, et al. STRATOS 1 and 2: considerations in clinical trial design for a fully human monoclonal antibody in severe asthma. Clin Invest 5 (2015), 701–711.
20. Baverel, PG, White, N, Vicini, P, Karlsson, MO, Agoram, B, Dose-exposure-response relationship of the investigational anti-interleukin-13 monoclonal antibody tralokinumab in patients with severe, uncontrolled asthma. Clin Pharmacol Ther 103 (2017), 826–835.
21. Sampson, HA, Munoz-Furlong, A, Campbell, RL, et al. Second symposium on the definition and management of anaphylaxis: summary report—Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 117 (2006), 391–397.
22. Lipkovich, I, Dmitrienko, A, Denne, J, Enas, G, Subgroup identification based on differential effect search—a recursive partitioning method for establishing response to treatment in patient subpopulations. Stat Med 30 (2011), 2601–2621.
23. Lipkovich, I, Dmitrienko, A, Strategies for identifying predictive biomarkers and subgroups with enhanced treatment effect in clinical trials using SIDES. J Biopharm Stat 24 (2014), 130–153.
24. Tepper, RS, Wise, RS, Covar, R, et al. Asthma outcomes: pulmonary physiology. J Allergy Clin Immunol 129:suppl 3 (2012), S65–S87.
25. Hanania, NA, Korenblat, P, Chapman, KR, et al. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med 4 (2016), 781–796.
26. Russell, RJ, FitzGerald, M, Backer, V, et al. Effect of the interleukin-13 neutralising monoclonal antibody, tralokinumab, on eosinophilic airway inflammation in uncontrolled moderate to severe asthma (MESOS): a randomised placebo-controlled phase 2 clinical trial. Lancet Respir Med, 2018 published online May 21. http://dx.doi.org/10.1016/S2213-2600(18)30201-7.
27. Wenzel, S, Castro, M, Corren, J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet 388 (2016), 31–44.
28. Regeneron Pharmaceuticals. Regeneron and Sanofi announce positive dupilumab topline results from phase 3 trial in uncontrolled persistent asthma. https://www.prnewswire.com/news-releases/regeneron-and-sanofi-announce-positive-dupilumab-topline-results-from-phase-3-trial-in-uncontrolled-persistent-asthma-300516839.html, Sept 11, 2017. (Accessed 28 March 2018)
29. Shiobara, T, Chibana, K, Watanabe, T, et al. Dipeptidyl peptidase-4 is highly expressed in bronchial epithelial cells of untreated asthma and it increases cell proliferation along with fibronectin production in airway constitutive cells. Respir Res, 17, 2016, 28.
30. Takayama, G, Arima, K, Kanaji, T, et al. Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J Allergy Clin Immunol 118 (2006), 98–104.
31. Pavord, ID, Afzalnia, S, Menzies-Gow, A, Heaney, LG, The current and future role of biomarkers in type 2 cytokine-mediated asthma management. Clin Exp Allergy 47 (2017), 148–160.
32. Genentech, Novartis. XOLAIR® (omalizumab): highlights of prescribing information. http://www.gene.com/download/pdf/xolair_prescribing.pdf, 2017. (Accessed 15 September 2017)
33. Bagnasco, D, Ferrando, M, Varricchi, G, Puggioni, F, Passalacqua, G, Canonica, GW, Anti-interleukin 5 (IL-5) and IL-5Ra biological drugs: efficacy, safety, and future perspectives in severe eosinophilic asthma. Front Med, 4, 2017, 135.
34. Corren, J, Parnes, JR, Wang, L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med 377 (2017), 936–946.
35. Horváth, I, Barnes, PJ, Loukides, S, et al. A European Respiratory Society technical standard: exhaled biomarkers in lung disease. Eur Respir J 49 (2017), 1–26.
36. Wenzel, SE, Emergence of biomolecular pathways to define novel asthma phenotypes. Type-2 immunity and beyond. Am J Respir Cell Mol Biol 55 (2016), 1–4.
37. Chibana, K, Trudeau, JB, Mustovich, AT, et al. IL-13 induced increases in nitrite levels are primarily driven by increases in inducible nitric oxide synthase as compared with effects on arginases in human primary bronchial epithelial cells. Clin Exp Allergy 38 (2008), 936–946.
38. Karelina, T, Voronova, V, Demin, O, Colice, G, Agoram, BM, A mathematical modeling approach to understanding the effect of anti-interleukin therapy on eosinophils. CPT Pharmacometrics Syst Pharmacol 5 (2016), 608–616.
39. Massanari, M, Holgate, ST, Busse, WW, Jimenez, P, Kianifard, F, Zeldin, R, Effect of omalizumab on peripheral blood eosinophilia in allergic asthma. Respir Med 104 (2010), 188–196.
40. Evans, PM, O'Connor, BJ, Fuller, RW, Barnes, PJ, Chung, KF, Effect of inhaled corticosteroids on peripheral blood eosinophil counts and density profiles in asthma. J Allergy Clin Immunol 91 (1993), 643–650.
41. Bleecker, ER, FitzGerald, JM, Chanez, P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 388 (2016), 2115–2127.
42. FitzGerald, JM, Bleecker, ER, Nair, P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 388 (2016), 2128–2141.
43. Ortega, HG, Liu, MC, Pavord, ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 371 (2014), 1198–1207.
44. McNicholl, DM, Stevenson, M, McGarvey, LP, Heaney, LG, The utility of fractional exhaled nitric oxide suppression in the identification of nonadherence in difficult asthma. Am J Respir Crit Care Med 186 (2012), 1102–1108.
45. Lisspers, K, Teixeira, P, Blom, C, et al. Are pharmacological randomised controlled clinical trials relevant to real-life asthma populations? A protocol for an UNLOCK study from the IPCRG. NPJ Prim Care Respir Med, 26, 2016, 16016.